98%
921
2 minutes
20
Fluid and solute transporters of the retinal pigment epithelium (RPE) are core components of the outer blood-retinal barrier. Characterizing these transporters and their role in retinal homeostasis may provide insights into ocular function and disease. Here, we describe RPE defects in mice, which exhibit hypopigmented patches in the central retina. Mapping and nucleotide sequencing of mice revealed a disrupted 5' splice donor sequence in , a sodium bicarbonate cotransporter gene. expression was reduced 19.7-fold in RPE relative to controls, and alternative splice variants were detected. SLC4A5 was localized to the Golgi apparatus of cultured human RPE cells and in apical and basal membranes. Fundus imaging, optical coherence tomography, microscopy, and electroretinography (ERG) of mice revealed retinal detachment, hypopigmented patches corresponding to neovascular lesions, and retinal folds. Detachment worsened and outer nuclear layer thickness decreased with age. ERG a- and b-wave response amplitudes were initially normal but declined in older mice. The direct current ERG fast oscillation and light peak were reduced in amplitude at all ages, whereas other RPE-associated responses were unaffected. These results link a new mutation to subretinal fluid accumulation and altered light-evoked RPE electrophysiological responses, suggesting that SLC4A5 functions at the outer blood-retinal barrier.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875008 | PMC |
http://dx.doi.org/10.3390/ijms23042220 | DOI Listing |
Retina
September 2025
Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA.
Purpose: To report outcomes of suprachoroidal hemorrhage (SCH).
Methods: Retrospective non-randomized study of eyes with SCH from two sites (1/1/2013-12/31/2022). The primary outcome was the 6-month change in visual acuity (VA).
Retina
September 2025
Department of Ophthalmology, St. Michael's Hospital/Unity Health Toronto, Toronto, Ontario, Canada.
Purpose: To report reattachment rate (RR) of pars plana vitrectomy-suprachoroidal viscopexy (VIT-SCVEXY) for rhegmatogenous retinal detachment (RRD) repair. Additionally, this study compares the anatomic reattachment rate and functional outcomes of VIT-SCVEXY vs pars plana vitrectomy with traditional scleral buckle (PPV-SB) at postoperative month 3 and final follow-up.
Methods: A retrospective cohort study conducted at St.
Retina
September 2025
Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, MA, USA.
Purpose: To investigate associations among expanded field swept-source optical coherence tomography angiography (SS-OCTA) biomarkers and the development of tractional retinal detachment (TRD) in patients with proliferative diabetic retinopathy (PDR).
Methods: Patients with PDR without TRD at baseline were imaged with SS-OCTA. Quantitative and qualitative OCTA metrics were independently evaluated by two trained graders.
Purpose: To assess how transitioning from an Aflibercept to a Faricimab intravitreal treatment impacts retinal structures and functional aspects in patients with neovascular age related macular degeneration (nAMD) in a real-life setting.
Patients And Methods: A retrospective clinical study including 49 patients (57 eyes) with nAMD at the Department of Ophthalmology and Optometry, Kepler University Hospital, Linz, Austria was performed. The patients, who had previously been receiving monthly Aflibercept injections with an unsatisfactory treatment response, were switched to intravitreal Faricimab and followed-up between 12/2022 and 12/2023.
Acta Ophthalmol
September 2025
Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden.
Purpose: To evaluate visual, anatomical and safety outcomes of aflibercept 8 mg in previously treated patients with neovascular age-related macular degeneration (nAMD).
Methods: This retrospective study included nAMD patients switched to aflibercept 8 mg from prior anti-VEGF therapies at Sahlgrenska University Hospital between February 2024 and February 2025. Data on best-corrected visual acuity (BCVA), central retinal thickness (CRT), pigment epithelial detachment (PED) height, fluid status, treatment intervals, time to fluid recurrence and adverse events were collected.